Xiaojia Wang, MD, PhD

Research interests: Breast diseases, cancer screening and early diagnosis, comprehensive treatment of breast cancer, molecular typing and classification treatment of breast cancer.

Xiaojia Wang, MD/PhD, is Professor and former director of medical oncology(Breast), Zhejiang Cancer Hospital; Hangzhou Institute of Medical（HIM) , Chinese Academy of Sciences. Assistant Dean of Zhejiang Cancer Hospital. He is a member of ASCO,ESMO,CSCO et al, and a visiting scholar of the University of Pennsylvania in the United States(2007). Currently, he is the deputy director of Zhejiang Cancer Intelligent Diagnosis and Molecular Technology Research Center, the deputy chairman of the breast cancer expert committee of the Chinese Society of Clinical Oncology (CSCO), the standing member of the breast cancer professional committee and the standing member of the medical ethics committee of the Chinese Anti-Cancer Association, the member of the onco-cardiology group of the Cardiovascular Branch of the Chinese Medical Association, the vice chairman of the Yangtze River Delta Cancer Association, chairman of the Medical Oncology Branch of Zhejiang Medical Association, Chairman of the breast cancer Professional Committee of Zhejiang Anti-Cancer Association, Vice Chairman of the Immunology Society of Zhejiang Province, Vice President of Zhejiang Translational Medicine Association and President of Precision Medicine Branch.

Dr. Wang participated in the writing of more than 20 domestic guidelines and expert consensus, presided over more than 20 national key research and development programs, international cooperation projects, NSFC, subprojects of the Ministry of Health, provincial major science and technology projects and key research and development plans, provincial natural funds, science and technology departments, provincial and ministerial co construction, provincial key Chinese medicine and other topics, published more than 300 papers, nearly 20 invention patents. He has published more than 100 SCI articles, more than 10 volumes of chief (translator/reviewer) editor works (including one English monograph).He leaded more than 100 international, domestic and investigator clinical trials (including more than 20 Leading PI projects), and published relevant clinical research results in TOP journals such as N Engl J Med., Lancet Oncol, JAMA Oncol, Nat Med, et al. He also participated in dozens of international conference for poster exchanges, mini oral, such as the 2023 ASCO Breakthrough mini Oral, 2024 ESMO mini Oral, and 2024 SABCS mini Oral, et al. In 2024, he assumed the role of guest editor for the Chinese special issue of Cancer (ISSN:1097-0142).